Skip to main content

Sonder Medicine uses extracellular vesicles from the vitreous humor as a potent vector to efficiently deliver recombinant proteins into the sensory tissue of the eye, the retina. Their proprietary technology can transport various payloads, including therapeutic proteins, nucleic acids and antibodies into the tissues of the human eye.


Aufbau Medical Innovations Ltd., wholly owns Sonder Medicine Inc., doing business as Sonder Research X in the United States.